Focused Bodywork as Facilitated Communication: Cautionary Perspectives on Touch in Psychedelic Therapy

The U.S. Food and Drug Administration declined to approve Lykos Therapeutics’ application for MDMA-assisted therapy, following the recommendation of its advisory committee. The decision marks a significant regulatory setback for psychedelic-assisted treatments. The text does not provide details on the reasons for the denial or any clinical trial results.

Study at a glance

Abstract

On August 9, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Lykos Therapeutics’ application for MDMA-assisted therapy (MDMA-AT), in alignment with the recommendation of its i...